Published in PLoS One on September 25, 2015
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science (2010) 10.69
Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol (2002) 8.31
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
siRNA-directed inhibition of HIV-1 infection. Nat Med (2002) 6.36
Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A (2002) 6.09
Modulation of HIV-1 replication by RNA interference. Nature (2002) 5.90
Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science (2001) 5.39
RNA-triggered gene silencing. Trends Genet (1999) 5.36
Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature (2013) 3.90
Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science (2012) 3.53
Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J Virol (2002) 3.42
Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol (2004) 3.23
Immune clearance of highly pathogenic SIV infection. Nature (2013) 3.15
Antimicrobial properties of chitosan and mode of action: a state of the art review. Int J Food Microbiol (2010) 2.54
Vaginal microbicides and the prevention of HIV transmission. Lancet Infect Dis (2008) 2.25
Human immunodeficiency virus type 1 pathobiology studied in humanized BALB/c-Rag2-/-gammac-/- mice. J Virol (2006) 2.24
Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. J Immunol (2002) 2.04
HIV and HLA class I: an evolving relationship. Immunity (2012) 1.91
Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev (2001) 1.87
Vaccine-induced CD8+ T cells control AIDS virus replication. Nature (2012) 1.78
Topical microbicides to prevent HIV: clinical drug development challenges. Annu Rev Pharmacol Toxicol (2009) 1.76
Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. J Virol (2003) 1.73
BLT-humanized C57BL/6 Rag2-/-γc-/-CD47-/- mice are resistant to GVHD and develop B- and T-cell immunity to HIV infection. Blood (2013) 1.57
DNA-polycation nanospheres as non-viral gene delivery vehicles. J Control Release (1998) 1.46
Chitosans for gene delivery. Adv Drug Deliv Rev (2001) 1.45
Lentivirus-mediated RNA interference of DC-SIGN expression inhibits human immunodeficiency virus transmission from dendritic cells to T cells. J Virol (2004) 1.37
Negative feedback inhibition of HIV-1 by TAT-inducible expression of siRNA. Nat Biotechnol (2004) 1.34
Superior human leukocyte reconstitution and susceptibility to vaginal HIV transmission in humanized NOD-scid IL-2Rγ(-/-) (NSG) BLT mice. Virology (2011) 1.23
Rapid evolution of HIV-1 to functional CD8⁺ T cell responses in humanized BLT mice. Sci Transl Med (2012) 1.21
Chitosan-based vector/DNA complexes for gene delivery: biophysical characteristics and transfection ability. Pharm Res (1998) 1.18
Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model. Virology (2012) 1.12
Generation of improved humanized mouse models for human infectious diseases. J Immunol Methods (2014) 1.08
Choosing CCR5 or Rev siRNA in HIV-1. Nat Biotechnol (2003) 1.00
Development and characterization of chitosan-PEG-TAT nanoparticles for the intracellular delivery of siRNA. Int J Nanomedicine (2013) 0.96
Inhibition of HIV-1 multiplication by antisense U7 snRNAs and siRNAs targeting cyclophilin A. Nucleic Acids Res (2004) 0.95
Epidemiology: Sexual transmission of HIV in Africa. Nature (2003) 0.95
HLA-B*57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice. J Virol (2014) 0.94
Anti-HIV-1 activity of low molecular weight sulfated chitooligosaccharides. Carbohydr Res (2009) 0.94
Attenuation of dengue virus infection by adeno-associated virus-mediated siRNA delivery. Genet Vaccines Ther (2004) 0.89
Human immune responses and potential for vaccine assessment in humanized mice. Curr Opin Immunol (2013) 0.89
Antimicrobial action of water-soluble β-chitosan against clinical multi-drug resistant bacteria. Int J Mol Sci (2015) 0.88
Engineering tenofovir loaded chitosan nanoparticles to maximize microbicide mucoadhesion. Eur J Pharm Sci (2011) 0.87
Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis. BMC Infect Dis (2012) 0.87
Maxizymes and small hairpin-type RNAs that are driven by a tRNA promoter specifically cleave a chimeric gene associated with leukemia in vitro and in vivo. Cancer Res (2003) 0.86
Comparative biophysical properties of tenofovir-loaded, thiolated and nonthiolated chitosan nanoparticles intended for HIV prevention. Nanomedicine (Lond) (2014) 0.85
Inhibition of SARS-CoV replication by siRNA. Antiviral Res (2005) 0.84
Preparation and characterization of nonaarginine-modified chitosan nanoparticles for siRNA delivery. Carbohydr Polym (2012) 0.82
Recent advances in humanized mice: accelerating the development of an HIV vaccine. J Infect Dis (2013) 0.81
Detection of transmission clusters of HIV-1 subtype C over a 21-year period in Cape Town, South Africa. PLoS One (2014) 0.80
Nanotechnology Applications to HIV Vaccines and Microbicides. J Glob Infect Dis (2012) 0.78
Anti-HIV activities of novel synthetic peptide conjugated chitosan oligomers. Int J Biol Macromol (2014) 0.77
Update on HIV in Western Europe. Curr HIV/AIDS Rep (2014) 0.77
HIV-1 epidemiology and circulating subtypes in the countryside of South Brazil. Rev Soc Bras Med Trop (2015) 0.77
Formulation and evaluation of mucoadhesive microspheres of tenofovir disoproxil fumarate for intravaginal use. Curr Drug Deliv (2014) 0.76